Following a post on tools for discovery of secretome biomarkers in biological samples, a recent publication by Torres et al. depicts how some of these tools (i.e. antibody arrays) can be used to find new biomarkers relevant for pancreatic cancer.
In this study, Torres and co-workers used an antibody array that detects 507 human secretome markers, an
d they compared serum of patients with pancreatic cancer vs. healthy controls.
They found a series of new biomarkers, of which the most relevant ones were Fibroblast Growth Factor 10 (FGF-10), Keratinocyte Growth Factor-2 (KGF-2), 11 Interferon Inducible T-cell alpha Chemokine (I-TAC), chemokine [C-X-C motif] ligand 11 (CXCL11), Oncostatin M (OSM), Osteoactivin/Glycoprotein Nonmetastatic Melanoma Protein B, and Stem Cell Factor (SCF), which were significantly overexpressed.
Moreover, they also found some markers which were differentially expressed in response to treatment with Gemcitabine and Erlotinib (CD30 ligand/Tumor Necrosis Factor superfamily Member 8 (TNFSF8), Chordin-like 2, FGF-10/KGF-2, Growth/Differentiation Factor 15, I-TAC/CXCL11, OSM, and SCF).
Congratulations to the whole team (specially Sonia and Carolina) for this nice publication that helps advancing in the fight against cancer!
Would you like to share your experiences using antibody arrays for biomarker discovery? Add your comments below!
